Table 6.
Relation between QR of methylated RASSF1A and tumor stage
| Stage I | Stage II | Stage III | Stage IV | Stages II–IV |
|---|---|---|---|---|
| 37.15 | 0 | 69.66 | 0 | 0 |
| 0 | 22.8 | 2 | 0 | 22.8 |
| 16.6 | 0 | 92.89 | 0 | |
| 1.37 | 7.94 | 0 | 7.94 | |
| 0 | 147.57 | 0 | 147.57 | |
| 0 | 0 | 416.86 | 0 | |
| 67.44 | 72.11 | 418.78 | 72.11 | |
| 0 | 222.3 | 51.62 | 222.3 | |
| 65.05 | 883.1 | 0 | 883.1 | |
| 0 | 0 | 208.93 | 0 | |
| 0 | 11.07 | 11.07 | ||
| 0 | 222.33 | 222.33 | ||
| 0 | 69.66 | |||
| 0 | 2 | |||
| 0 | 92.89 | |||
| 0 | ||||
| 0 | ||||
| 416.86 | ||||
| 418.78 | ||||
| 51.62 | ||||
| 0 | ||||
| 208.93 | ||||
| 0 | ||||
| 0 | ||||
| Mean | ||||
| 12.5 | 132 | 126 | 119 | |
Mann–Whitney U-test P<0.05. Stage I vs. stage II P=0.0588, stage I vs. stage III P=0.0319, stage I vs. stage II–IV P=0.0349. For one NSCLC stage was not known.